Select dosing information for KADCYLA in metastatic breast cancer

Patient Selection: Assessment of HER2 protein overexpression and/or HER2 gene amplification should be performed using FDA-approved tests specific for breast cancers by laboratories with demonstrated proficiency.1

Recommended dosing

Do not substitute trastuzumab for or with KADCYLA.

3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unmanageable toxicity.1

Do not administer KADCYLA at doses greater than 3.6 mg/kg.

Dosing schedule1

Closely monitor the infusion site for possible subcutaneous infiltration during drug administration.

Recommended dose reduction schedule for adverse events1

Do not re-escalate the KADCYLA dose after a dose reduction is made.

Dose modification guidelines for MBC1

ALT=alanine transaminase; AST=aspartate transaminase; CHF=congestive heart failure; LVEF=left ventricular ejection fraction; ULN=upper limit of normal.

Preparation and dose considerations

Get more information about administering KADCYLA, including considerations before and during treatment, as well as how to prepare the infusion.

Preparation and dose considerations

Get more information about administering KADCYLA, including considerations before and during treatment, as well as how to prepare the infusion.